Abogen licenses mRNA-encoded T-cell engager to Novartis in deal worth up to $7.8 billion

Abogen Biosciences has entered a licensing and option agreement with Novartis for ABO2203, an mRNA-encoded T-cell engager for autoimmune diseases. Abogen will receive $575 million upfront, with potential milestone payments up to $7.2 billion. The deal includes options for additional RNA programs. ABO2203 uses mRNA to produce CD19xCD3 molecules in vivo, aiming to reset B cells. Clinical trials showed promising results with minimal adverse events.

Novartis will pay $575 million upfront to license an experimental mRNA-based autoimmune therapy from Abogen Biosciences, a Chinese firm, to bolster its drug pipeline. The NIH has spent its $34 billion fiscal 2026 research grant allocation, but funding delays and opacity are hindering scientific progress, according to STAT.

Novartis has agreed to a deal with Abogen Biosciences, potentially worth up to $7.8 billion. The Swiss pharmaceutical company is investing in the Chinese biotech firm, according to the report. This deal highlights growing pharmaceutical collaborations in China.

Novartis licensed Abogen's mRNA therapy ABO2203 for autoimmune diseases in a $7.8B deal, including $575M upfront. Abogen may receive $7.2B more for milestones. Novartis gains exclusive options for Abogen's RNA platform. The deal follows Novartis' recent clinical setbacks, costing $30B in market cap. Investors note the deal's front-loaded structure reduces risk.

Novartis will pay Abogen $575m upfront for mRNA programs, with potential milestones reaching $7.2bn. The deal covers ABO2203, an mRNA-encoded T-cell engager for autoimmune diseases, and options for other assets. Novartis aims to leverage Abogen's RNA platform for innovative therapies. The agreement is subject to regulatory approvals.

Novartis entered a licensing agreement with Abogen for RNA-encoded therapeutic Abo2203, paying $575M upfront and up to $7.2B in milestones. AstraZeneca and Daiichi Sankyo partnered with Summit Therapeutics to test Datroway with ivonescimab in cancer trials. PwC predicts $300B in pharma M&A this year.